Skip to main content

Table 1 Baseline characteristics classified according to (mRS 0-1;2-6)

From: Association of neuroimaging markers of cerebral small vessel disease with short-term outcomes in patients with minor cerebrovascular events

Variables

Good outcome (mRS Score 0–1) at 90 d, n = 317

Poor outcome (mRS Score 2–6) at 90 d, n = 71

P Value

Age, y, mean ± SD

65.50 ± 11.14

71.23 ± 9.98

< 0.01

Women, n (%)

198 (62%)

39 (55%)

0.239

Admission NIHSS, median (IQR)

1.25 (1–2.25)

2.25 (2–3)

< 0.01

Past medical history, n (%)

 Hypertension

262 (83%)

62 (87%)

0.337

 Coronary artery disease

38 (12%)

13 (18%)

0.154

 Atrial fibrillation

38 (12%)

14 (20%)

0.084

 Diabetes mellitus

114 (36%)

28 (39%)

0.583

 Hyperlipidemia

127 (40%)

35 (30%)

0.449

 Stroke

49 (15%)

12 (17%)

0.621

 Hematencephalon

32 (10%)

8 (11%)

0.712

Smoking, n (%)

61 (19%)

12 (17%)

0.648

Alcohol, n (%)

48 (15%)

8 (11%)

0.401

Carotid atherosclerosis, n (%)

221 (76%)

38 (78%)

0.838

TOAST classification, n (%)

  

0.349

 Large artery atherosclerosis

69 (55%)

19 (70%)

 

 Small vessel disease

44 (35%)

8 (30%)

 Cardioembolic

10 (8%)

0 (0%)

 Undetermined

3 (2%)

0 (0%)

Clinical variables, median (IQR)

 FBG, mmol/L

5.42 (4.86–6.75)

5.63 (4.88–6.65)

0.493

 HbAIc, %

6.00 (5.50–7.30)

5.90 (5.60–9.00)

0.203

 TC, mmol/L

4.16 (3.59–4.67)

5.42 (2.94–4.81)

0.255

 TG, mmol/L

1.31 (0.96–1.86)

1.29 (0.93–1.51)

0.456

 LDL-C, mmol/L

2.38 (1.99–2.87)

2.25 (1.45–2.96)

0.070

 H-CRP, mg/L

1.70 (0.80–6.93)

3.10 (0.70–18.30)

0.220

 LP-PLA2, ng/mL

143.00 (97.00–261.50)

284.00 (208.00–391.00)

< 0.01

 Hcy, umol/L

12.50 (9.90–15.50)

11.30 (10.10–14.60)

0.328

 D-Dimer, mg/L

0.34 (0.25–0.53)

0.27 (0.38–0.69)

0.414

SVD burden score, median (IQR)

3 (2–3)

3 (1–3)

0.894

 SVD score is 0, n (%)

4 (1%)

2 (3%)

 

 SVD score is 1, n (%)

60 (19%)

16 (23%)

 SVD score is 2, n (%)

94 (30%)

15 (21%)

 SVD score is 3, n (%)

132 (42%)

30 (42%)

 SVD score is 4, n (%)

27 (9%)

8 (11%)

WMH, n (%)

227 (18%)

62 (87%)

0.006

lacunes, n (%)

226 (71%)

59 (83%)

0.042

PVS, n (%)

219 (69%)

45 (63%)

0.351

CMB, n (%)

46 (15%)

11 (16%)

0.833

Fazekas score, median (IQR)

4 (2.5–6)

5 (4–6)

< 0.01

 Periventricular WMH score

2 (1–3)

3 (2–3)

< 0.01

 Deep WMH score

3 (1–3)

3 (2–3)

0.020

SVD burden score after 3 months, median (IQR)

3 (2–3)

3 (2–3)

0.667

 SVD score is 0, n (%)

4 (1%)

2 (3%)

 

 SVD score is 1, n (%)

57 (18%)

13 (18%)

 SVD score is 2, n (%)

96 (30%)

18 (25%)

 SVD score is 3, n (%)

133 (42%)

29 (41%)

 SVD score is 4, n (%)

27 (9%)

9 (13%)

Fazekas score after 3 months, median (IQR)

4 (2.5–6)

5 (4–6)

< 0.01

 Periventricular WMH score

2 (1–3)

3 (2–3)

< 0.01

 Deep WMH score

3 (1–3)

3 (2–3)

0.022

  1. Note: signifificant difference (P < 0.05)
  2. FBG Fasting blood glucose, HbAIc Glycosylated hemoglobin, TC Total cholesterol, TG Triglyceride, LDL-C Low density lipoprotein cholesterol, H-CRP High C-reactive protein, Hcy Homocysteine, LP-PLA2 Lipoprotein-associated phospholipase A2, SVD Cerebral small vascular diseases, WMH White matter hyperintensity, PVS Enlarged perivascular spaces, CMB Cerebral microbleeds